ストックスクリーナーアプリを入手
2.83
0.70%
-0.02
プレマーケット:
2.83
Sana Biotechnology Inc (SANA) 最新ニュース
Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.14, Implies 230% Upside - TradingView
Sana Biotechnology raises $69M through ATM share sale - MSN
SANA: Gene-modified islet and in vivo CAR T therapies advance toward pivotal trials and key data in 2024 - TradingView
Sana Biotechnology, Inc. - MLQ.ai
SANA SEC FilingsSana Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Bilenker Joshua H. - Moomoo
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director NELSEN ROBERT - Moomoo
Sana Biotechnology Shareholders Reelect Directors and Ratify Auditor - TipRanks
Sana Biotechnology (SANA) director awarded options for 90,000 shares at $2.96 - Stock Titan
Sana Biotechnology (SANA) director granted 90,000 stock options at $2.96 strike - Stock Titan
Director Michelle Seitz gets 90,000 Sana (SANA) stock options - Stock Titan
Sana Biotechnology (SANA) grants director 90,000 stock options at $2.96 - Stock Titan
Sana Biotechnology (SANA) director receives 90,000-share stock option grant - Stock Titan
Sana Biotechnology (SANA) director granted 90,000 stock options at $2.96 - Stock Titan
Sana (SANA) director awarded 90,000 stock options vesting in 2027 - Stock Titan
Sana Biotechnology (SANA) shareholders elect directors, ratify Ernst & Young LLP - Stock Titan
SANA Stock Chart | SANA BIOTECHNOLOGY INC (NASDAQ:SANA) - ChartMill
SANA: Hypoimmune cell therapy and in vivo CAR T trials to start this year, with data expected in 12 months - TradingView
SANA Stock Price, Quote & Chart | SANA BIOTECHNOLOGY INC (NASDAQ:SANA) - ChartMill
Law firm probes Sana Biotech officers for possible shareholder duty breaches - Pluang
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Stream Sana Biotechnology's June investor talks live online - Stock Titan
Seattle InnoSana and Bothell I Following up with ZenLedger - The Business Journals
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - Quantisnow
Sana Biotechnology to Present at June 2026 Investor Conferences - The Manila Times
Sana Biotechnology to present updates at two major healthcare investor conferences in June 2026 - Pluang
RA Capital affiliates report 18.75M Sana Biotechnology shares (NASDAQ: SANA) - Stock Titan
Sana Biotechnology | SCHEDULE 13G: Others - Moomoo
Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $3.07 - Moomoo
InvestingPro Fair Value spotted Sana Biotech overvaluation early By Investing.com - Investing.com Canada
Sana Biotech rises as Mayo Clinic partners for diabetes therapy - MSN
Sana Biotechnology Shares Fall on Sale of $69 Million in Shares Through At-The-Market Facility - Moomoo
Sana Biotechnology Raises $69 Million Through Equity Offering - TipRanks
Sana Biotechnology (SANA) sells 21.6M shares to raise about $69M - Stock Titan
Sana Biotechnology | 8-K: Current report - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Sana Biotechnology Raises $69 Million Through ATM Equity Offering - Moomoo
Sana Biotechnology raises $69 million through stock sale By Investing.com - Investing.com Australia
Sana Biotechnology raises $69 million through stock sale - Investing.com
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through Its At-the-Market (ATM) Facility - 富途牛牛
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs - The Manila Times
Sana presents preclinical data on in vivo CAR T therapy SG293 - Investing.com UK
Sana presents preclinical data on in vivo CAR T therapy SG293 By Investing.com - Investing.com India
BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
SANA: Progress in gene-edited islet and in vivo CAR-T therapies positions the pipeline for major milestones - TradingView
Sana Biotechnology Presents Preclinical Data for In Vivo - GlobeNewswire
A Quick Look at Today's Ratings for Sana Biotechnology(SANA.US), With a Forecast Between $7 to $16 - Moomoo
Sana Biotechnology | 10-Q: Q1 2026 Earnings Report - Moomoo
Sana Biotechnology gains on Mayo Clinic partnership progress despite EPS miss By Investing.com - Investing.com South Africa
Sana Biotechnology | 8-K: Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates - Moomoo
Sana Biotechnology gains on Mayo Clinic partnership progress despite EPS miss - Investing.com India
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):